Health Risk Factor Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Austin Research Institute
Findings describe new data in cancer vaccines research
March 22nd, 2005
Cancer vaccines research advances have been reported from Australia, the United States and France. Study 1: Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumor challenge in mice. "Peptide based vaccines offer practical advantages, but unmodified peptides usually require an adjuvant or delivery vehicle to promote immunogenicity. When peptides containing ovalbumin (OVA) derived CD4 and CD8 T cell epitopes were conjugated to 0.05 micron nano-beads, they gave strong immune responses and inhibition of growth of tumor cells expressing the CD8...
Source: Health Risk Factor Week (2005-03-22)
|
